A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
The study will continue until approximately 52 weeks after the last participant is randomized. The maximum duration of an individual's participation is estimated to be ~120 weeks and will depend on duration of study enrollment.
Inclusion Criteria:
Exclusion Criteria:
Clearwater, Florida 33756, United States
Largo, Florida 33777, United States
Safety Harbor, Florida 34695, United States
Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Air C1027AAP, Argentina
São José do Rio Preto, São Paulo 15090000, Brazil
Nanjing, Jiangsu 210000, China
Gurugramam, Haryana 122018, India
Mumbai, Maharashtra 400012, India
New Delhi, National Capital Territory of Delhi 110002, India
New Delhi, National Capital Territory of Delhi 110062, India
Ramat Gan, Central District 5262100, Israel
Hadera, Northern District 3810101, Israel
Haifa, Northern District 3109601, Israel